At this year’s CPhI, mineral producer Omya will focus on Omyapharm 500-OG, an excipient made from calcium carbonate and tribasic calcium phosphate. The highly porous inactive ingredient facilitates the production of tablets and granules with excellent compactability, good mechanical stability, high absorption capacity and rapid disintegration. At the company’s booth, CPhI visitors will be able to see tablet samples and experience the multiple benefits of Omyapharm first hand.

 

Case studies have shown that Omyapharm 500-OG is an excellent filler-binder for tablets in dry granulation processes. It combines good compactability with a fast disintegration time, thanks to the excellent porosity and specific surface properties of the highly structured mineral. This results in harder tablets at low compression forces. In addition, Omyapharm® can be used as an extremely efficient carrier for converting oils and liquids into compressible powders.

 

In a recent study, scientists also confirmed the ability of Omyapharm to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel. The tablets were well accepted by the volunteers and – in correlation with the in vitro model – disintegrated quickly in vivo. This study proves that Omyapharm can be successfully used as an excipient in ODTs without causing any unpleasant sensations in the mouth.

 

During CPhl 2018, the company’s team of pharma experts will be available to answer technical questions and discuss further possible applications. With its state-of-the-art, in-house laboratory for solid dosage forms, Omya is able to provide specific formulation services. This includes creating innovative mineral solutions for the pharmaceutical market and supporting customers in the development of optimal applications.